Zacks analyst blog spotlights Amazon, Sanofi, Target, Humana and PNC Financial Services

[ad_1]

For immediate release

Chicago, IL – November 14, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Amazon AMZN, Sanofi SNY, Target Corp. TGT, Humana Inc. HUM and The PNC Financial Services Group, Inc. PNC.

Here are highlights from Friday’s analyst blog:

Best Inventory Reports for Amazon, Sanofi, and Target

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Amazon, Sanofi and Target Corp. These research reports have been handpicked from the approximately 70 reports published by our team of analysts today.

You can see all research reports from today here >>>

Shares of Amazon.co.uk fell -45.2% over the past year compared to the -48.6% decline in the Internet Industry – Zacks Commerce and the -17.1% decline in the S&P Index 500.

Amazon’s near-term outlook weighs on the view that the company’s strong growth during Covid has resulted from revenue being pulled forward from future periods that need to be recognized in future quarters. The company is also believed to have over-hired during the pandemic, which has significantly increased its cost base.

Those short-term headwinds aside, it’s gaining on strong Prime momentum thanks to lightning-fast delivery services and a strong content portfolio. Another plus point is the strengthening of relationships with third-party sellers.

Also, the growing momentum of Amazon Music helps nicely. Additionally, AWS’s high adoption rate contributes to the company’s cloud dominance. Expanding the AWS service portfolio continually helps Amazon gain traction with customers.

Plus, strong Alexa skills and expanding smart home product portfolio are positives. Additionally, the company’s strong global presence and solid momentum among small and medium-sized businesses remain tailwinds. Given the aforementioned facts, the Zacks analyst expects 2022 revenue to be up 11% from 2021.

(You can read the full research report on Amazon.com here >>>)

Sanofi Shares have underperformed industry Zacks Large Cap Pharmaceuticals over the past year (-12.7% vs. +10.7%). The company faces headwinds, including weak performance of diabetes drugs and generic competition for many drugs. However, Sanofi’s specialty medicine unit is on a solid footing, especially with the steady expansion of the Dupixent label.

Dupixent has become Sanofi’s key revenue driver. With revenue accelerating outside the United States and multiple approvals for new indications expected in the near future, its sales are expected to be higher. Sanofi has a leading vaccine portfolio, which has become the main revenue driver. Its R&D pipeline is solid.

Several data readings are expected in 2022. Sanofi’s Consumer unit is showing sales growth outpacing the market. Sanofi has also launched several new drugs over the past two years and is expanding its pipeline through mergers and acquisitions deals.

(You can read the full research report on Sanofi here >>>)

Target stocks are down -24.7% this year against Walmart’s -1.5% decline and the S&P 500 index’s -18.2% decline. The market was unwilling to give credit to Target for the inventory growth issue that surfaced in its April quarter report in May. This is a relatively favorable setup for the stock if next week’s quarterly report turns out to be better than the market fears.

Target has deployed resources to improve omnichannel capabilities, introduce new brands, renovate stores and expand same-day delivery options to provide customers with a seamless shopping experience.

Target has made multiple changes to its business model to adapt and stay relevant in the dynamic retail landscape. These contributed to the top line. We believe Target’s attempt to resize inventory is a step in the right direction, as demand has shifted toward consumer staples and away from discretionary categories.

However, this hurt margins, as seen in the second quarter of fiscal 2022, but allowed the company to better position to gain market share. The Zacks analyst expects revenue to grow 3% and 4.2% in the third and fourth quarters, respectively. For the second half of the year, we expect a sequential improvement in operating margin.

(You can read the full research report on Target here >>>)

Other noteworthy reports we feature today include Humana Inc. and The PNC Financial Services Group, Inc.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Sanofi (SNY): Free Stock Analysis Report

The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report

Target Corporation (TGT): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

[ad_2]
Source link